Guru Ownership Trend
Guru Analysis for Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 5 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $5.24 M.
Top institutional holders include Cliff Asness and Renaissance Technologies (RenTech).
Institutional sentiment is currently Bullish. This is evidenced by a $4.41 M net inflow during the quarter.
Recent activity highlights Cliff Asness who increased their stake by 780.0%. Conversely, Chuck Royce reduced exposure by 31.4%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for Entrada Therapeutics, Inc. (TRDA)
Major holders include Cliff Asness ($5.15 M), Renaissance Technologies (RenTech) ($1.41 M), Louis Moore Bacon ($772,800). According to the latest reported data, 5 tracked investment managers collectively hold approximately 1.11 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $4.41 M, with 2 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 0 fully exited TRDA. The total reported sell value was $360,838.85.
Yes, 1 managers opened new positions in TRDA, and 1 increased their existing holdings. The total reported buy value was $4.77 M.